Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Payables (2020 - 2025)

Historic Payables for Rapid Micro Biosystems (RPID) over the last 6 years, with Q3 2025 value amounting to $3.6 million.

  • Rapid Micro Biosystems' Payables rose 5422.93% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year increase of 5422.93%. This contributed to the annual value of $2.5 million for FY2024, which is 2848.45% up from last year.
  • According to the latest figures from Q3 2025, Rapid Micro Biosystems' Payables is $3.6 million, which was up 5422.93% from $3.3 million recorded in Q2 2025.
  • Over the past 5 years, Rapid Micro Biosystems' Payables peaked at $5.4 million during Q4 2022, and registered a low of $1.2 million during Q1 2024.
  • For the 5-year period, Rapid Micro Biosystems' Payables averaged around $2.8 million, with its median value being $2.6 million (2021).
  • Its Payables has fluctuated over the past 5 years, first tumbled by 6374.65% in 2023, then skyrocketed by 12637.46% in 2025.
  • Quarter analysis of 5 years shows Rapid Micro Biosystems' Payables stood at $3.9 million in 2021, then soared by 37.63% to $5.4 million in 2022, then crashed by 63.65% to $2.0 million in 2023, then rose by 28.48% to $2.5 million in 2024, then skyrocketed by 41.7% to $3.6 million in 2025.
  • Its last three reported values are $3.6 million in Q3 2025, $3.3 million for Q2 2025, and $2.6 million during Q1 2025.